Works matching IS 21641153 AND DT 2021 AND VI 11 AND IP 4
Results: 8
FDA Approved Truseltiq for Metastatic Cholangiocarcinoma with the FGFR2 Biomarker.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2021, v. 11, n. 4, p. 234
- Publication type:
- Article
Rylaze FDA Approved as Part of a Treatment Regimen for Pediatric Leukemia and Lymphoma.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2021, v. 11, n. 4, p. 234
- Publication type:
- Article
Truseltiq (Infigratinib) New Targeted Therapy FDA Approved for Advanced or Metastatic Cholangiocarcinoma Harboring FGFR2 Alterations.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2021, v. 11, n. 4, p. 230
- By:
- Publication type:
- Article
Comparing Cyclophosphamide-Based versus Etoposide-Based Chemomobilization for Autologous Hematopoietic-Cell Transplant in Patients with Lymphoma.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2021, v. 11, n. 4, p. 222
- By:
- Publication type:
- Article
Acute-Onset Congestive Heart Failure After 5-Fluorouracil Administration in a Patient with Colon Cancer.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2021, v. 11, n. 4, p. 216
- By:
- Publication type:
- Article
Management of Acyclovir-Resistant Herpes Simplex Virus Infection in Patients Undergoing Hematopoietic Stem-Cell Transplantation.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2021, v. 11, n. 4, p. 210
- By:
- Publication type:
- Article
Myeloablative and Reduced-Intensity Preparative Regimens for Allogeneic Transplant in the Outpatient versus Inpatient Setting in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2021, v. 11, n. 4, p. 197
- By:
- Publication type:
- Article
Safety of Inactivated Vaccines in Patients Receiving Immune Checkpoint Inhibitors.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2021, v. 11, n. 4, p. 186
- By:
- Publication type:
- Article